X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (5) 5
humans (5) 5
index medicus (4) 4
male (4) 4
oncology (4) 4
aged (3) 3
middle aged (3) 3
adult (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
cancer (2) 2
cancer vaccines - adverse effects (2) 2
cancer vaccines - therapeutic use (2) 2
carcinoma, non-small-cell lung - therapy (2) 2
cisplatin - administration & dosage (2) 2
deoxycytidine - administration & dosage (2) 2
deoxycytidine - analogs & derivatives (2) 2
disease-free survival (2) 2
hematology, oncology and palliative medicine (2) 2
lung cancer (2) 2
lung neoplasms - mortality (2) 2
lung neoplasms - pathology (2) 2
management (2) 2
membrane glycoproteins - adverse effects (2) 2
membrane glycoproteins - therapeutic use (2) 2
mortality (2) 2
radiotherapy (2) 2
surgery (2) 2
survival (2) 2
tumors (2) 2
[ sdv.can ] life sciences [q-bio]/cancer (1) 1
adenocarcinoma (1) 1
age factors (1) 1
analysis (1) 1
anemia - etiology (1) 1
antigens (1) 1
antigens, cd - analysis (1) 1
antigens, differentiation, t-lymphocyte - analysis (1) 1
antimetabolites, antineoplastic (1) 1
antimetabolites, antineoplastic - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
bayesian analysis (1) 1
bevacizumab (1) 1
bevacizumab - administration & dosage (1) 1
biomarkers (1) 1
biomarkers, tumor - blood (1) 1
cancer therapies (1) 1
cancer vaccines (1) 1
cannabis smoking (1) 1
carboplatin - administration & dosage (1) 1
carcinoma, non-small-cell lung (1) 1
carcinoma, non-small-cell lung - chemistry (1) 1
carcinoma, non-small-cell lung - drug therapy (1) 1
carcinoma, non-small-cell lung - immunology (1) 1
carcinoma, non-small-cell lung - mortality (1) 1
carcinoma, non-small-cell lung - pathology (1) 1
cd16 antigen (1) 1
cd56 antigen (1) 1
cd56 antigen - analysis (1) 1
cd69 antigen (1) 1
chemotherapy (1) 1
chemotherapy, adjuvant (1) 1
chi-square distribution (1) 1
cisplatin (1) 1
clinical neurology (1) 1
clinical study (1) 1
clinical trials (1) 1
cohort studies (1) 1
colorectal neoplasms - radiotherapy (1) 1
colorectal neoplasms - surgery (1) 1
complications (1) 1
cytokines (1) 1
deoxycytidine (1) 1
double-blind (1) 1
double-blind method (1) 1
drug abuse (1) 1
educational status (1) 1
employment - statistics & numerical data (1) 1
epidemiology (1) 1
epidermal growth factor receptors (1) 1
erlotinib hydrochloride - administration & dosage (1) 1
europe (1) 1
experience (1) 1
expression (1) 1
fatigue (1) 1
fatigue - etiology (1) 1
fc receptors (1) 1
flap (1) 1
france - epidemiology (1) 1
gene (1) 1
hospitals (1) 1
immunotherapy (1) 1
immunotherapy - adverse effects (1) 1
inequalities (1) 1
interleukin 2 (1) 1
interleukin-2 (1) 1
interleukin-2 - genetics (1) 1
interleukin-2 - immunology (1) 1
interleukins (1) 1
intestinal fistula - etiology (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 12, pp. 1125 - 1133
Summary Background Chemotherapy is the standard of care for advanced stages of non-small-cell lung cancer (NSCLC). TG4010 is a targeted immunotherapy based on... 
Hematology, Oncology and Palliative Medicine | DOUBLE-BLIND | PROGNOSTIC-FACTORS | GENE | ONCOLOGY | EXPRESSION | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Vaccinia virus - genetics | Antimetabolites, Antineoplastic - administration & dosage | Cisplatin - administration & dosage | Cancer Vaccines - therapeutic use | Interleukin-2 - immunology | Time Factors | Adult | Female | Chemotherapy, Adjuvant | Carcinoma, Non-Small-Cell Lung - pathology | Risk Assessment | Deoxycytidine - administration & dosage | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Cancer Vaccines - adverse effects | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Carcinoma, Non-Small-Cell Lung - immunology | Disease-Free Survival | Interleukin-2 - genetics | Carcinoma, Non-Small-Cell Lung - therapy | Lung Neoplasms - immunology | Membrane Glycoproteins - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mucin-1 - immunology | Vaccines, Synthetic | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Membrane Glycoproteins - adverse effects | Deoxycytidine - analogs & derivatives | Mucin-1 - genetics | Index Medicus | Interleukin-2 | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Life Sciences | Cancer Vaccines | Membrane Glycoproteins | Antineoplastic Combined Chemotherapy Protocols | Cisplatin | Mucin-1 | Vaccinia virus | Deoxycytidine | Antimetabolites, Antineoplastic | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 212 - 223
Summary Background MUC1 is a tumour-associated antigen expressed by many solid tumours, including non-small-cell lung cancer. TG4010 is a modified vaccinia... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | MVA-MUC1-IL2 | PROSTATE-CANCER | VACCINE | Predictive Value of Tests | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Fatigue - etiology | Male | Cisplatin - administration & dosage | Antigens, CD - analysis | Antigens, Differentiation, T-Lymphocyte - analysis | Neutropenia - etiology | Cancer Vaccines - therapeutic use | Receptors, IgG - analysis | Mucin-1 - analysis | Lectins, C-Type - analysis | Female | Paclitaxel - administration & dosage | Lymphocytes - chemistry | Anemia - etiology | Bevacizumab - administration & dosage | Double-Blind Method | Lung Neoplasms - chemistry | Lymphocyte Activation | CD56 Antigen - analysis | Deoxycytidine - administration & dosage | Erlotinib Hydrochloride - administration & dosage | Carboplatin - administration & dosage | Cancer Vaccines - adverse effects | Lung Neoplasms - therapy | Immunotherapy - adverse effects | Biomarkers, Tumor - blood | Disease-Free Survival | Carcinoma, Non-Small-Cell Lung - therapy | Membrane Glycoproteins - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pemetrexed - administration & dosage | Aged | Membrane Glycoproteins - adverse effects | Deoxycytidine - analogs & derivatives | Antigens | Fc receptors | Hospitals | Interleukins | Immunotherapy | Mucins | Clinical trials | Product development | Lung cancer, Non-small cell | Analysis
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.